Nicholas P Restifo Selected Research

T-Cell Antigen Receptors (T-Cell Receptor)

1/2020	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
1/2019	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
1/2018	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
3/2016	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
4/2015	Adoptive cell transfer as personalized immunotherapy for human cancer.
3/2015	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
1/2014	Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.
4/2013	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.
4/2013	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
2/2013	Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas P Restifo Research Topics

Disease

172	Neoplasms (Cancer) 01/2022 - 01/2002
74	Melanoma (Melanoma, Malignant) 02/2021 - 01/2002
9	Experimental Melanoma 06/2013 - 08/2004
7	Neoplasm Metastasis (Metastasis) 08/2016 - 06/2002
7	Communicable Diseases (Infectious Diseases) 10/2013 - 04/2005
5	Virus Diseases (Viral Diseases) 11/2019 - 06/2006
4	Inflammation (Inflammations) 07/2017 - 03/2006
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 05/2008
3	Fowlpox 01/2016 - 08/2003
3	Infections 02/2015 - 05/2009
3	Testicular Neoplasms (Testicular Cancer) 10/2011 - 01/2006
2	Weight Loss (Weight Reduction) 01/2020 - 05/2006
2	Autoimmune Diseases (Autoimmune Disease) 07/2017 - 09/2010
2	Colorectal Neoplasms (Colorectal Cancer) 03/2016 - 03/2011
2	Pancreatic Neoplasms (Pancreatic Cancer) 03/2016 - 12/2014
2	Sarcoma (Soft Tissue Sarcoma) 03/2015 - 03/2011
2	Lymphoma (Lymphomas) 12/2014 - 11/2010
2	Vitiligo 06/2013 - 09/2010
2	Lymphopenia (Lymphocytopenia) 03/2010 - 04/2005
2	Vaccinia 04/2006 - 11/2002
2	Thrombocytopenia (Thrombopenia) 04/2005 - 01/2002
1	Bites and Stings (Sting) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Uterine Cervical Dysplasia 01/2018
1	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2017
1	Teratoma (Teratoid Tumor) 11/2017
1	Carcinogenesis 11/2017

Drug/Important Bio-Agent (IBA)

63	AntigensIBA 01/2021 - 06/2002
26	Interleukin-2 (IL2)IBA 05/2017 - 08/2003
24	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 02/2004
24	CytokinesIBA 01/2020 - 09/2003
22	VaccinesIBA 05/2017 - 01/2002
18	Peptides (Polypeptides)IBA 01/2019 - 06/2002
14	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 09/2002
14	Proteins (Proteins, Gene)FDA Link 11/2017 - 06/2002
13	EpitopesIBA 01/2019 - 08/2003
12	Chimeric Antigen ReceptorsIBA 01/2021 - 11/2010
9	AutoantigensIBA 05/2017 - 09/2002
8	LigandsIBA 01/2019 - 08/2003
8	InterleukinsIBA 03/2012 - 08/2003
8	Differentiation AntigensIBA 12/2010 - 10/2002
7	Interleukin-12 (IL 12)IBA 01/2020 - 09/2010
7	Interleukin-15 (Interleukin 15)IBA 08/2011 - 02/2004
6	Monophenol Monooxygenase (Tyrosinase)IBA 12/2010 - 04/2006
5	HLA-A*02:01 antigenIBA 03/2015 - 08/2003
4	Glycoproteins (Glycoprotein)IBA 12/2014 - 09/2003
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 08/2010
4	interferon tauIBA 06/2013 - 03/2004
4	Interleukin-17 (Interleukin 17)IBA 12/2011 - 07/2009
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2009 - 04/2005
4	Cancer VaccinesIBA 05/2006 - 11/2002
3	PotassiumIBA 01/2019 - 01/2016
3	HLA-A Antigens (HLA-A)IBA 01/2018 - 02/2005
3	Transcription Factors (Transcription Factor)IBA 02/2016 - 05/2006
3	Monoclonal AntibodiesIBA 12/2014 - 09/2005
3	Interferon-gamma (Interferon, gamma)IBA 06/2013 - 07/2009
3	DNA VaccinesIBA 10/2011 - 01/2003
3	DisulfidesIBA 10/2011 - 06/2010
3	interleukin-21 (interleukin 21)IBA 08/2011 - 01/2005
3	fludarabineIBA 05/2009 - 04/2005
3	gp100 Melanoma AntigenIBA 11/2005 - 08/2003
2	Histocompatibility Antigens Class IIBA 12/2021 - 01/2019
2	InterferonsIBA 01/2020 - 01/2017
2	Messenger RNA (mRNA)IBA 11/2019 - 01/2006
2	Initiator Codon (Start Codon)IBA 01/2019 - 02/2005
2	Chemokine ReceptorsIBA 05/2017 - 10/2006
2	Oxygen (Dioxygen)IBA 01/2017 - 08/2016
2	Codon (Codons)IBA 03/2016 - 02/2005
2	Toll-Like Receptor AgonistsIBA 01/2016 - 05/2011
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2012 - 11/2010
2	Toll-Like Receptors (Toll-Like Receptor)IBA 05/2011 - 09/2007
2	Protein Subunit VaccinesIBA 07/2010 - 05/2006
2	EnzymesIBA 06/2010 - 01/2003
2	Amino Acids FDA Link 10/2007 - 08/2003
2	DNA (Deoxyribonucleic Acid)IBA 05/2006 - 05/2003
2	Biomarkers (Surrogate Marker)IBA 11/2005 - 09/2004
2	beta 2-Microglobulin (beta 2 Microglobulin)IBA 02/2005 - 09/2003
2	beta-Galactosidase (Lactaid)IBA 11/2002 - 01/2002
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2021
1	vadimezanIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2020
1	MorpholinosIBA 11/2019
1	AntibodiesIBA 11/2019
1	Untranslated Regions (Untranslated Region)IBA 01/2019
1	epidermal growth factor receptor VIIIIBA 01/2019
1	Histones (Histone)IBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 01/2019
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2019
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018

Therapy/Procedure

91	Immunotherapy 01/2022 - 01/2002
56	Therapeutics 01/2022 - 06/2002
10	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 04/2008
7	Drug Therapy (Chemotherapy) 10/2016 - 09/2003
3	Transplantation 12/2010 - 04/2005
2	Aftercare (After-Treatment) 05/2015 - 05/2009
2	Intravenous Administration 09/2003 - 01/2002
1	Hematopoietic Stem Cell Transplantation 01/2021
1	Radiotherapy 11/2019